Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 552Colorectal Neoplasms 246Neoplasms 232Prostatic Neoplasms 221Carcinoma, Non-Small-Cell Lung 196Stomach Neoplasms 153Leukemia, Myeloid, Acute 149Carcinoma, Hepatocellular 147Lung Neoplasms 137Rectal Neoplasms 135Multiple Myeloma 133Nasopharyngeal Carcinoma 112Colonic Neoplasms 106Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Lymphoma 85Uterine Cervical Neoplasms 83Pancreatic Neoplasms 82Lymphoma, Large B-Cell, Diffuse 79Ovarian Neoplasms 78Leukemia 78Head and Neck Neoplasms 77Esophageal Neoplasms 74Lymphoma, Follicular 72Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 65Recurrence 64Leukemia, Lymphocytic, Chronic, B-Cell 59Lymphoma, Non-Hodgkin 58Pain 56

Interventions

pyrotinib 1pertuzumab 1disitamab vedotin 1Trastuzumab 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER × HER2-positive Metastatic Breast Cancer × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡